Publication date: 5th October 2020
Conclusions:
- GRS offers enhanced predictive capability for CHD when added to traditional risk calculators.
- Variability in effectiveness underscores the need for population-specific adaptations and more extensive validation studies.
- While GRS is a promising tool, its integration into clinical practice requires further evidence, particularly for non-European populations.
- CiC GRS is also associated with an increased hazard of CAD in different and ethnically diverse populations, supporting the usefulness of incorporating genetic information into CV risk assessment among minority subjects in the US
